**Purpose:**

To provide instructions for ordering, receiving, storing, and selecting COVID-19 Convalescent plasma (CCP) collected from patients who recovered from COVID-19 infection for transfusion to patients who are ill with COVID-19 through Emergency Use Authorization (EUA) with the FDA.

**Policy:**

* Orders for CCP components are placed through Epic.
* CCP components are stored at ≤ -18 C segregated from standard plasma units to prevent inadvertent use by non-intended patients.
* CCP components are ordered on an “as needed” basis from the blood supplier by HMC TSL staff upon receipt of order for CCP for the patient.
* Transfusion reactions related to the transfusion of CCP will be reported to HMC TSL and worked up per standard policy.

**Procedure notes and limitations:**

* CCP components are to be allocated and issued only to intended patient.
* Units not transfused to the intended participant will either be discarded or returned to blood supplier. Place unit in quarantine, report on QIM form, and notify TSL Manager.

**Principle**

CCP components are collected from recovered patients who are otherwise eligible for blood donation and the units will be fully licensed. CCP components will be labeled with the following statement; “CAUTION: New Drug-Limited by Federal (or US) law to Investigational Use”.

**Procedure:**

|  |  |  |
| --- | --- | --- |
| **Step** | **Action** | **Related Documents** |
| 1 | Physician will place order in Epic. |  |
| 2 | Receive plasma order through Order Receipt/Modify (ORM) | SQ Order Entry Process |
| 3 | Place order in BloodHub   * Fax a copy of the “Request for COVID-19 Convalescent Plasma” to BWNW IM * BWNW will notify TSL when CCP is packaged. | BloodHub Training Materials  BWNW Request for COVID-19 Convalescent Plasma Form |
| 4 | Contact courier service for pickup from BWNW IM |  |
| 5 | Receive plasma into inventory   * Inspect unit * CCP will arrive with a tie tag or face label with “CAUTION: New Drug-Limited by Federal (or US) law to Investigational Use”. * Enter “CCPL” as an antigen/antibody. This will translate to COVID-19 Convalescent Plasma * Additional Tie Tags or stickers may be on the unit regarding A and/or B titer. Add “LTP” as an antigen/antibody if present. * Type A units: “No High Titer Antibody to B Antigen Detected” * Type O units: “No Hight Titer Antibody to A and/or B Antigen Detected” * Store CCP in designated area of ≤ -18C freezer * Notify floor of product availability | Order Distribution Report (ODR)  Receiving Blood Products into Inventory  Blood Product Inspection Policy  Visual Inspection of Plasma Products  SQ Blood Product Entry  Blood Product Storage Policy |
| 6 | Clinical team will initiate transfuse task and release will print, Once printed:   * Thaw CCP, preferentially using the Helmer Quickthaw System * Perform Blood Component Prep using BCP * Label check unit and new label * Allocate thawed plasma to patient * Issue unit to floor | Blood Product Release form from Epic (BPR)  Thawing Products Using the Helmer Quickthaw System  Thawing Products using the ARK Microwave Plasma Defroster  Visual inspection of Plasma Products  SQ Preparation of Thawed Plasma  SQ Blood Label Check (BLC) and Verification  Manual Label Verification Form  SQ Blood Order Processing  Blood Product Issue Process  SQ Blood Product Issue |

**References:**

Technical Manual. Bethesda, MD: AABB Press, current edition

Standards for Blood Banks and Transfusion Services. Bethesda, MD: AABB Press, current edition

Investigational COVID-19 Convalescent Plasma Guidance for Industry: FDA September 2, 2020